Published in Gut on December 01, 1998
Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol (2003) 1.29
MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis (2009) 1.20
Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol (2003) 1.17
Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer (2006) 1.16
Gastrin-stimulated gastric epithelial cell invasion: the role and mechanism of increased matrix metalloproteinase 9 expression. Biochem J (2002) 1.11
A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol (2004) 1.10
cDNA array analysis of cag pathogenicity island-associated Helicobacter pylori epithelial cell response genes. Infect Immun (2001) 1.07
Balance between polyoma enhancing activator 3 and activator protein 1 regulates Helicobacter pylori-stimulated matrix metalloproteinase 1 expression. Cancer Res (2006) 1.01
The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer. PLoS One (2014) 0.98
The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer (2001) 0.97
Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). Diagn Pathol (2013) 0.93
Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MT1-MMP in gastric cancer. BMC Cancer (2009) 0.91
Lymph node micrometastasis and its correlation with MMP-2 expression in gastric carcinoma. World J Gastroenterol (2006) 0.91
MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol (2006) 0.90
A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer. J Cancer Res Clin Oncol (2004) 0.90
Matrix metalloproteinase-14 is a negative prognostic marker for patients with gastric cancer. Dig Dis Sci (2013) 0.90
Expression of MMP-2,TIMP-2 protein and the ratio of MMP-2/TIMP-2 in gallbladder carcinoma and their significance. World J Gastroenterol (2002) 0.88
Matrix metalloproteinase-1 (MMP-1) Promoter polymorphisms are well linked with lower stomach tumor formation in eastern Indian population. PLoS One (2014) 0.88
Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. Acta Pharmacol Sin (2009) 0.85
Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer. Gastric Cancer (2009) 0.85
Increased protein expression of matrix metalloproteinases -1, -3, and -9 and TIMP-1 in patients with gluten-sensitive enteropathy. Dig Dis Sci (2006) 0.84
Gastrin stimulates MMP-1 expression in gastric epithelial cells: putative role in gastric epithelial cell migration. Am J Physiol Gastrointest Liver Physiol (2015) 0.83
mRNA profiling of the cancer degradome in oesophago-gastric adenocarcinoma. Br J Cancer (2012) 0.83
The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer. Int J Clin Oncol (2007) 0.82
Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer. Gastric Cancer (2006) 0.81
Expression of the matrix metalloproteases 2, 14, 24, and 25 and tissue inhibitor 3 as potential molecular markers in advanced human gastric cancer. Dis Markers (2014) 0.80
Differential gene expression pattern in early gastric cancer by an integrative systematic approach. Int J Oncol (2012) 0.80
DNA ploidy analysis and expression of MMP-9, TIMP-2, and E-cadherin in gastric carcinoma. World J Gastroenterol (2005) 0.80
Human desmoid fibroblasts: matrix metalloproteinases, their inhibitors and modulation by Toremifene. BMC Cancer (2005) 0.80
A single nucleotide polymorphism in the matrix metalloproteinase 2 promoter is closely associated with high risk of nasopharyngeal carcinoma in Cantonese from southern China. Chin J Cancer (2011) 0.80
Presence of 46 kDa gelatinase on the outer membrane of Leptospira. Curr Microbiol (2011) 0.77
A zymography analysis of proteinase activity present in Leptospira. Curr Microbiol (2010) 0.77
Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression. J Control Release (2017) 0.77
Contribution of matrix metalloproteinases-1 genotypes to gastric cancer susceptibility in Taiwan. Biomedicine (Taipei) (2017) 0.76
Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer. Oncotarget (2016) 0.76
Downregulation of CD147 by chitooligosaccharide inhibits MMP-2 expression and suppresses the metastatic potential of human gastric cancer. Oncol Lett (2014) 0.76
Correlations of polymorphisms in matrix metalloproteinase-1, -2, and -7 promoters to susceptibility to malignant gliomas. Asian J Neurosurg (2016) 0.75
Anti-metastatic activity of fangchinoline in human gastric cancer AGS cells. Oncol Lett (2016) 0.75
Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma. J Histochem Cytochem (2016) 0.75
Distinct biological events generated by ECM proteolysis by two homologous collagenases. Proc Natl Acad Sci U S A (2016) 0.75
Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem (1987) 34.69
A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (1994) 9.31
Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J (1991) 8.29
Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res (1995) 2.50
Biology of tumour metastasis. Lancet (1992) 2.44
Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med (1996) 2.42
Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J (1993) 2.28
The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol (1992) 2.19
Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature (1997) 2.17
Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst (1991) 2.15
Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res (1993) 1.97
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem (1996) 1.92
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer (1996) 1.71
Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol (1998) 1.64
Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res (1993) 1.45
Type IV collagenases in invasive tumors. Breast Cancer Res Treat (1993) 1.43
Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem (1996) 1.35
Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther (1996) 1.35
Expression of laminin, collagen IV, fibronectin, and type IV collagenase in gastric carcinoma. An immunohistochemical study of 87 patients. Cancer (1994) 1.31
Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res (1994) 1.30
Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther (1993) 1.29
Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res (1996) 1.27
Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res (1995) 1.27
Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer (1996) 1.25
Metalloproteinases and tissue damage. Br J Rheumatol (1991) 1.18
Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer (1994) 1.14
Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst (1995) 1.13
Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol (1995) 1.10
Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol (1997) 1.05
Defining the invasive phenotype of proximal gastric cancer cells. Cancer (1994) 1.04
Expression pattern of metalloproteinases and their inhibitors changes with the progression of human sporadic colorectal neoplasia. Diagn Mol Pathol (1993) 0.97
Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am J Pathol (1994) 0.92
Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice. Cancer (1996) 0.92
Further studies on the structure of the glycogen-bound form of protein phosphatase-1 from rabbit skeletal muscle. Eur J Biochem (1987) 0.89
Computational sequence analysis of the tissue inhibitor of metalloproteinase family. J Protein Chem (1997) 0.86
A simple enzyme-linked immunosorbent assay (ELISA) for the neuron-specific gamma isozyme of human enolase (NSE) using monoclonal antibodies raised against synthetic peptides corresponding to isozyme sequence differences. J Immunol Methods (1992) 0.82
Immunohistochemistry of neurone specific enolase with gamma subunit specific anti-peptide monoclonal antibodies. J Clin Pathol (1993) 0.79
Sequence of chicken ovalbumin mRNA. Nature (1978) 6.73
Loss of Gastro-intestinal-specific Antigen in Neoplasia. Br Med J (1962) 2.59
Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med (1996) 2.42
An analysis of the anatomical basis for the mechanical response to motor nerve stimulation of the rat vas deferens. J Physiol (1977) 1.97
Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res (1997) 1.84
Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol (2001) 1.67
The complete amino-acid sequence of hen ovalbumin. Eur J Biochem (1981) 1.66
Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol (1998) 1.64
Plasmin, fibrin degradation and angiogenesis. Nat Med (1996) 1.59
Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem (1999) 1.33
Incorporation of 6-thioguanosine and 4-thiouridine into RNA. Application to isolation of newly synthesised RNA by affinity chromatography. Eur J Biochem (1978) 1.28
Monoclonal antibodies to human respiratory syncytial virus and their use in comparison of different virus isolates. J Gen Virol (1984) 1.22
Complete amino acid sequence of the neurone-specific gamma isozyme of enolase (NSE) from human brain and comparison with the non-neuronal alpha form (NNE). Eur J Biochem (1988) 1.21
A molecular approach to the complement system. Curr Top Cell Regul (1978) 1.16
The induction of azaguanine-resistant mutants in cultured Chinese hamster cells by reactive derivatives of carcinogenic hydrocarbons. Mutat Res (1973) 1.14
Complete nucleotide sequence of the gene for human C1 inhibitor with an unusually high density of Alu elements. Eur J Biochem (1991) 1.12
Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol (1993) 1.10
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer (2001) 1.09
Discrimination between Gyrodactylus salaris, G. derjavini and G. truttae (Platyhelminthes: Monogenea) using restriction fragment length polymorphisms and an oligonucleotide probe within the small subunit ribosomal RNA gene. Parasitology (1995) 1.09
Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol (2001) 1.08
Genomic and cDNA cloning of the human C1 inhibitor. Intron-exon junctions and comparison with other serpins. Eur J Biochem (1988) 1.08
Pelvic inflammatory disease and puerperal sepsis in Ethiopia. I. Etiology. Am J Obstet Gynecol (1980) 1.08
The sentinel pile and Sir Benjamin Collins Brodie. Surg Gynecol Obstet (1966) 1.08
Xenobiotic metabolising enzyme expression in colonic neoplasia. Gut (1993) 1.08
Application of laser capture microdissection and proteomics in colon cancer. Mol Pathol (2001) 1.07
Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett (1995) 1.06
Changes in DNA and RNA synthesis and associated enzyme activities after the stimulation of serum-depleted BHK21-C13 cells by the addition of serum. Exp Cell Res (1974) 1.06
The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br J Clin Pharmacol (1988) 1.05
Conservation of ribosomal RNA during compensatory renal hypertrophy. A major mechanism in RNA accretion. J Cell Biol (1976) 1.04
Expression of Wnt genes in early wound healing. Wound Repair Regen (1999) 1.04
The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma. Cancer (1993) 1.04
Primary structure of bovine complement activation fragment C4a, the third anaphylatoxin. Purification and complete amino acid sequence. Biochem J (1982) 1.03
The purification and characterization of bovine C4, the fourth component of complement. Biochem J (1979) 1.02
In situ hybridisation of albumin mRNA in normal liver and hepatocellular carcinoma with a digoxigenin labelled oligonucleotide probe. J Clin Pathol (1992) 1.01
Analysis of the nucleoprotein gene identifies distinct lineages of viral haemorrhagic septicaemia virus within the European marine environment. Virus Res (1999) 0.99
Purification and characterization of subcomponent C1q of the first component of bovine complement. Biochem J (1979) 0.99
Cytochrome P450 expression in oesophageal cancer. Gut (1994) 0.98
Molecular cloning of cDNA for human complement component C1s. The complete amino acid sequence. Eur J Biochem (1987) 0.98
Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form. Eur J Biochem (1998) 0.98
Babies of mothers with leprosy have small placentae, low birth weights and grow slowly. Br J Obstet Gynaecol (1980) 0.96
Thiol and disulphide contents of hen ovalbumin. C-terminal sequence and location of disulphide bond. Biochem J (1970) 0.96
The amino acid sequence of the small monomeric phosphoglycerate mutase from the fission yeast Schizosaccharomyces pombe. Biochem J (1994) 0.95
Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem Pharmacol (1998) 0.95
Proceedings: Observations on the origin of the complex mechanical response to motor nerve stimulation of the rat vas deferens. J Physiol (1976) 0.95
The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. J Pathol (1995) 0.94
The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr Cancer Drug Targets (2004) 0.94
The serine proteinase chain of human complement component C1s. Cyanogen bromide cleavage and N-terminal sequences of the fragments. Biochem J (1983) 0.94
Studies on the maintenance of cytochromes P-450 and b5, monooxygenases and cytochrome reductases in primary cultures of rat hepatocytes. FEBS Lett (1985) 0.92
Replacement of asparagine by aspartic acid in hen ovalbumin and a difference in immunochemical reactivity. Biochem J (1972) 0.92
Evidence for a soluble lymphocyte factor in the transplacental transmission of T-lymphocyte responses to Mycobacterium leprae. Nature (1976) 0.91
Complete amino acid sequences of five dimeric and four monomeric forms of metallothionein from the edible mussel Mytilus edulis. Eur J Biochem (1993) 0.91
The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HEPG2 hepatoma cells. Biochem Pharmacol (1993) 0.91
Prevalence of Epstein-Barr virus in the cervix. J Clin Pathol (1994) 0.90
Cytochrome P-450 localization in normal human adult and foetal liver by immunocytochemistry using a monoclonal antibody against human cytochrome P-450. Histochem J (1988) 0.90
Sequences of sixteen phosphoserine peptides from ovalbumins of eight species. Eur J Biochem (1981) 0.89
Structural comparison of ovalbumins from nine different species. Eur J Biochem (1970) 0.89
Limited proteolysis of beta 2-microglobulin at Lys-58 by complement component C1s. Eur J Biochem (1990) 0.89
Trends in mortality and hospital admission rates for abdominal aortic aneurysm in England and Wales, 1979-1999. Br J Surg (2005) 0.89
Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer (1999) 0.88
Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism. Biochem J (1989) 0.88
Monoclonal antibodies against human cytochrome P-450 recognizing different pregnenolone 16 alpha-carbonitrile-inducible rat cytochromes P-450. Biochem J (1987) 0.87
Antibodies against Mycobacterium leprae antigen 7 from birth to 18 months of age: an indicator of intra-uterine infection in leprosy. Clin Exp Immunol (1980) 0.87
Spot the differences: proteomics in cancer research. Lancet Oncol (2001) 0.87
Immunoglobulin concentration in mothers with leprosy and in healthy controls and their babies at the time of birth. Lepr Rev (1980) 0.87
Expression of cytochrome P450IA in breast cancer. Br J Cancer (1991) 0.87
The influence of culture medium composition on drug metabolising enzyme activities of the human liver derived Hep G2 cell line. FEBS Lett (1988) 0.87
Structure and activity of C1r and C1s. Philos Trans R Soc Lond B Biol Sci (1984) 0.85
Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br J Cancer (2004) 0.85
Enhanced expression of cytochrome P450 in stomach cancer. Br J Cancer (1998) 0.85
Variation in drug-metabolizing enzyme activities during the growth of human Hep G2 hepatoma cells. Xenobiotica (1990) 0.84
The plant mitochondrial F1-ATPase. The identity of the delta' (20 kDa) subunit. FEBS Lett (1990) 0.84
The relation of metabolism to macromolecular binding of the carcinogen benzo[a]pyrene, by mouse embryo cells in culture. Int J Cancer (1970) 0.84
IgA and IgM antibodies against Mycobacterium leprae in cord sera and in patients with leprosy: an indicator of intrauterine infection in leprosy. Scand J Immunol (1981) 0.84
Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder. Int J Exp Pathol (1995) 0.83
Trends in mortality rates for death-certificate-coded diabetes mellitus in an English population 1979-99. Diabet Med (2004) 0.83
A general method for affinity purification of complement component C3b using factor H-sepharose. Biochem J (1982) 0.83
Monocyte C1-inhibitor synthesis in patients with C1-inhibitor deficiency. Eur J Clin Invest (1989) 0.83
The purification and characterization of subcomponent C1s of the first component of bovine complement. Biochem J (1979) 0.83
Localization of microsomal epoxide hydrolase in normal and neoplastic human kidney. J Histochem Cytochem (1995) 0.82
Differences in adult and foetal human cytochrome P-450 forms recognized by monoclonal antibodies with specificity for the P450III family. Biochem J (1989) 0.82
Trends in mortality for cancers, comparing multiple- and underlying-cause rates, in an English population 1979-1999. Br J Cancer (2004) 0.82
Plant mitochondrial F1-ATPase. The presence of oligomycin-sensitivity-conferring protein (OSCP). Biochem J (1989) 0.82
Metabolism and macromolecular binding of dibenz(a,c)anthracene and dibenz(a,h)anthracene by mouse embryo cells in culture. Int J Cancer (1972) 0.82
A simple enzyme-linked immunosorbent assay (ELISA) for the neuron-specific gamma isozyme of human enolase (NSE) using monoclonal antibodies raised against synthetic peptides corresponding to isozyme sequence differences. J Immunol Methods (1992) 0.82
Dehydrogenase enzyme histochemistry on freeze-dried or fixed resin-embedded tissue. Histochem J (1988) 0.81
Onset of ribosome degradation during cessation of growth in BHK-21/C13 cells. Biochem J (1978) 0.81
Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours. Cancer Lett (1999) 0.80
Cytochrome P450IA expression in adult and fetal human liver. Carcinogenesis (1992) 0.80